New treatment recommendations for children with Acute Lymphoblastic Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the implementation of new treatment recommendations for children diagnosed with Acute Lymphoblastic Leukemia (ALL). It focuses on both standard and high-risk forms of ALL, introducing anthracycline induction and high-dose consolidation therapies. The study seeks to ensure the feasibility of these recommendations and aims for a complete remission rate of approximately 85% after induction treatment. Additionally, it will assess the long-term survival without relapse in patients achieving remission.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2

\-

Exclusion Criteria:

ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21

Where it's running

• CHU de Treichville à ABIDJAN
  Abidjan, Côte d’Ivoire Recruiting
• CHU Donka 030 BP 554
  Conakry, Guinea Recruiting
• Hôpital Aristide Le Dantec, Avenue Pasteur,
  Dakar, Senegal Recruiting

Study contacts

• Study coordinator: Ndella Ms DIOUF, MD
• Email: ndella.diouf@gfaop.org
• Phone: 00(221)77 656 49 13.

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New treatment approach for relapsed childhood leukemia using arsenic compounds

  This study is testing a new treatment using arsenic compounds combined with standard chemotherapy to see if it can help children with relapsed acute lymphoblastic leukemia feel better and have a better chance of recovery.

  Recruiting Phase 4 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05682131

• Therapeutic recommendations for children with Hodgkin lymphoma

  This study is trying to create a standard treatment plan for children with Hodgkin lymphoma to improve their care and reduce the side effects of radiation therapy.

  Recruiting French Africa Pediatric Oncology Group · Paris, France · NCT05407480

• Improving treatment recommendations for children with retinoblastoma in Africa

  This study is trying to see if better treatment recommendations and early diagnosis can help improve survival rates for children with retinoblastoma in Africa.

  Recruiting at 7 sites French Africa Pediatric Oncology Group · Ouagadougou and 6 other locations · NCT04425434

• Evaluating treatment recommendations for children with Burkitt's Lymphoma

  This study is trying to find better ways to diagnose and treat children with Burkitt's Lymphoma in Sub-Saharan Africa to improve their chances of recovery.

  Recruiting at 7 sites French Africa Pediatric Oncology Group · Ouagadougou and 6 other locations · NCT04425421

• Evaluating treatment recommendations for children with nephroblastoma

  This study looks at how well hospitals follow treatment guidelines for children with nephroblastoma who haven't had treatment yet, to see if sticking to these guidelines leads to better outcomes.

  Recruiting at 7 sites French Africa Pediatric Oncology Group · Ouagadougou and 6 other locations · NCT04423484

• Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa

  This study is collecting information about children with cancer in French-speaking Africa to help improve cancer care and treatment programs for them.

  Recruiting at 14 sites French Africa Pediatric Oncology Group · Ouagadougou and 13 other locations · NCT03803735

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.